CoChat
Sign Up
Cited by 210Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease

Galimberti, Daniela, Fenoglio, Chiara, Lovati, Carlo, Venturelli, Eliana, Guidi, Ilaria, Corrà, Barbara, Scalabrini, Diego, Clerici, Francesca +3 more·2006·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2005.10.007
Open this paper in CoChat — free account

Abstract

Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usefulness as an early AD biomarker would be possible only in combination with other molecules.

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2005.10.007

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased levels of chemokines and cytokines in plasma and cerebrospinal fluid are a very early event in Alzheimer's disease pathogenesis, even preceding clinical onset, as demonstrated by subjects with mild cognitive impairment who developed AD over time.

    “Indeed, chemokines and cytokines increased levels in plasma and CSF are a very early event in AD pathogenesis, even preceding the clinical onset of the disease, as demonstrated by subjects with MCI who developed AD over time, representing a crucial step in the progression of the disease [117,118,119].”

    From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [118]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., & Scarpini, E.
Affiliations
University of Milan (IT)
Corresponding author
Galimberti, Daniela
ORCID
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2006-12
Volume
27
Issue
12
Pages
1763-1768
ISSN
0197-4580 (ISSN-L)
DOI
10.1016/j.neurobiolaging.2005.10.007
OpenAlex
W1976829076
Cited by
209
References
37
Citations by year
2026: 4 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 15 · 2020: 10 · 2019: 15 · 2018: 10 · 2017: 10 · 2016: 12 · 2015: 10 · 2014: 13 · 2013: 10 · 2012: 3
FWCI
3.40
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
MCP-1, mild cognitive impairment, mild Alzheimer's disease, serum biomarkers, neuroinflammation, chemokines, peripheral blood mononuclear cells, disease progression, conversion to Alzheimer's disease
MeSH terms
Aged, Alzheimer Disease, Cognition Disorders, Female, Humans, Male, Biomarkers, Up-Regulation, Chemokine CCL2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review